Participants 25 96 4
early positron emission tomography-negative stage I/II Hodgkin lymphoma
Participants 311 366 4
patients with clinical stage I/II Hodgkin lymphoma (HL)
Participants 666 844 4
patients attaining a negative early PET scan after two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) as compared with standard combined-modality treatment
Participants 867 946 6
Patients age 15 to 70 years with untreated clinical stage I/II HL were eligible
Participants 1279 1315 7
The analysis included 1,137 patients
